Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial

With the Stanford Cancer Institute joining as a clinical trial partner, Tessa's Phase III trial for nose cancer (nasopharyngeal cancer) is now widely accessible across multiple locations in the U.S. The therapy is based on Tessa's Virus-Specific T cell ... Biopharmaceuticals, Oncology Tessa Therapeutics, nasopharyngeal cancer, T cell immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news